PhosphoBLOCKER Blocking Reagent | 고마바이오텍

특징

 

• 인단백질 blotting을 위해 제작된 blocking reagent 입니다.
• 일반적으로 사용하는 Dry milk 혹은 Serum보다 최상의 blocking 효과를 제공합니다.
• 백그라운드 증가 없이 low level의 인단백질 시그널을 향상시켜 줍니다.
• Western blot 과정 동안 인단백질 항원을 유지시킵니다.
• Dry 타입으로 제공되며, TBST나 PBST를 넣어 바로 녹여 사용할 수 있어, 간편합니다. 

사용 방법

1. Freshly prepare 5% PhosphoBLOCKER™ solution in TBST or PBST. 
2. Use the 5% PhosphoBLOCKER™ solution to block the blot. 
3. When probing the blot, use the 5% PhosphoBLOCKER™ solution to dilute primary and secondary antibodies.

실험 결과

Superior Blocking with PhosphoBLOCKER™ Blocking Reagent. A549 cell lysate was blocked with dry milk (top) or PhosphoBLOCKER™ reagent (bottom) before detection with anti-Phospho-p38 antibody.

사용 논문

1. Shimazaki, R. et al. (2021). Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Cell Oncol (Dordr). doi: 10.1007/s13402-021-00614-z.
2. Okada, R. et al. (2021). Low magnetic field promotes recombinant human BMP-2-induced bone formation and influences orientation of trabeculae and bone marrow-derived stromal cells. Bone Rep. doi: 10.1016/j.bonr.2021.100757.
3. Gong, Y. et al. (2020). Identification of PTPRσ-interacting proteins by proximity-labeling assay. J Biochem. doi: 10.1093/jb/mvaa141.
4. Kushioka, J. et al. (2020). A novel negative regulatory mechanism of Smurf2 in BMP/Smad signaling in bone. Bone Res. doi: 10.1038/s41413-020-00115-z.
5. Attili, I. et al. (2020). SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Transl Lung Cancer Res. 9(5):1810-1821. doi: 10.21037/tlcr-20-681.
6. Kushioka, J. et al. (2020). The small compound, TD-198946, protects against intervertebral degeneration by enhancing glycosaminoglycan synthesis in nucleus pulposus cells. Sci Rep. 10(1):14190. doi: 10.1038/s41598-020-71193-6.
7. Orthofer, M. et al. (2020). Identification of ALK in Thinness. Cell. 181(6):1246-1262.e22. doi: 10.1016/j.cell.2020.04.034.
8. Osrodek, M. et al. (2020). Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells. Cancer Manag Res. 12:7231-7250. doi: 10.2147/CMAR.S263767.
9. Chabloz, A. et al. (2020). Salmonella-based platform for efficient delivery of functional binding proteins to the cytosol. Commun Biol. 3(1):342. doi: 10.1038/s42003-020-1072-4.
10. Williams, J.J.L. et al. (2020). Investigation of Novel Cavin-1/Suppressor of Cytokine Signaling 3 (SOCS3) Interactions by Coimmunoprecipitation, Peptide Pull-Down, and Peptide Array Overlay Approaches. Methods Mol Biol. 2169:105-118. doi: 10.1007/978-1-0716-0732-9_10.
11. Orthofer, M. et al. (2020). Identification of ALK in Thinness. Cell. S0092-8674(20)30497-9. doi: 10.1016/j.cell.2020.04.034.
12. Zeng, X. et al. (2020). Effect of Low Dose of Berberine on the Radioresistance of Cervical Cancer Cells via a PI3K/HIF-1 Pathway under Nutrient Deprived Conditions. Int J Radiat Biol. doi: 10.1080/09553002.2020.1770358.
13. Koizumi, R. et al. (2020). Relationship between hemodynamic alteration and sympathetic nerve activation following a single oral dose of cinnamtannin A2. Free Radic Res. doi: 10.1080/10715762.2020.1759805.
14. Nihei, Y. et al. (2019). Poly-glycine-alanine exacerbates C9orf72 repeat expansion-mediated DNA damage via sequestration of phosphorylated ATM and loss of nuclear hnRNPA3. Acta Neuropathol. doi: 10.1007/s00401-019-02082-0.
15. Taniguchi, K. et al. (2019). α-Aminoisobutyric acid-containing amphipathic helical peptide-cyclic RGD conjugation as a potential drug delivery system for microRNA replacement therapy in vitro. Mol Pharm. doi: 10.1021/acs.molpharmaceut.9b00680.
16. Serrano-Regal, M.P. et al. (2019). Oligodendrocyte Differentiation and Myelination Is Potentiated via GABAB Receptor Activation. Neuroscience. pii: S0306-4522(19)30488-9. doi: 10.1016/j.neuroscience.2019.07.014.
17. Czyz, M. et al. (2019). Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program. Journal of Oncology. 2019:1697913. doi: 10.1155/2019/1697913.
18. Ashizawa, Y. et al. (2019). OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human Hepatocellular Carcinoma. Hepatology Communications. doi:10.1002/hep4.1361.
19. Bertran-Alamillo, J. et al. (2019). AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nat Commun. 10(1):1812. doi: 10.1038/s41467-019-09734-5.
20. Mielczarek-Lewandowska, A. et al. (2019). 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes. Apoptosis. doi: 10.1007/s10495-019-01542-y.
21. Nakada, S. et al. (2019). Roles of Pin1 as a Key Molecule for EMT Induction by Activation of STAT3 and NF-κB in Human Gallbladder Cancer. Ann Surg Oncol. 26(3):907-917. doi: 10.1245/s10434-018-07132-7.
22. Hartman, M.L. et al. (2019). Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells. Mol Carcinog. 58(4):588-602. doi: 10.1002/mc.22953.
23. Bemben, M.A. et al. (2019). Isoform-specific cleavage of neuroligin-3 reduces synapse strength. Mol Psychiatry. 24(1):145-160. doi: 10.1038/s41380-018-0242-y.
24. Ohara, M. et al. (2018). Extracellular Vesicles from Amnion-Derived Mesenchymal Stem Cells Ameliorate Hepatic Inflammation and Fibrosis in Rats. Stem Cells Int. 2018:3212643. doi: 10.1155/2018/3212643.
25. Heishima, K. et al. (2018). Short-Term Administration of Single-Agent Toceranib in Six Cases of Inoperable Massive Canine Hepatocellular Carcinoma. J Am Anim Hosp Assoc. doi: 10.5326/JAAHA-MS-6788.
26. Rodriguez-Perez, A.I. et al. (2018). Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death. Neurotherapeutics. 15(4):1063-1081. doi: 10.1007/s13311-018-0646-z.
27. Palomo-Guerrero, M. et al. (2018). Uridine-5'-Triphosphate Partially Blocks Differentiation Signals and Favors a more Repair State in Cultured rat Schwann Cells. Neuroscience. 372:255-265. doi: 10.1016/j.neuroscience.2018.01.010.
28. Zalesna, I., et al. (2017). Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro. PLoS One. 12(8):e0183498. doi: 10.1371/journal.pone.0183498.
29. Surdo, N.C. et al. (2017). FRET biosensor uncovers cAMP nano-domains at β-adrenergic targets that dictate precise tuning of cardiac contractility. Nat Commun. 8:15031. doi: 10.1038/ncomms15031.
30. Hartman, M.L. et al. (2017). Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells. Lab Invest. doi: 10.1038/labinvest.2016.140.

주문정보

견적문의 제품담기

주문정보 - Cat No, PRODUCT, SIZE, 수량 등 항목으로 구성되어있습니다.

	Product	Cat.No.	Size	Maker	Qty	Data Sheet	MSDS

전체보기

추천제품

관련제품

견적문의 제품담기

주문정보 - Cat No, PRODUCT, SIZE, 수량 등 항목으로 구성되어있습니다.

	Product	Cat.No.	Size	Maker	Qty	Data Sheet	MSDS

전체보기

자료

웨비나/Video